Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LENZUMESTROCEL for Knee Cartilage Defects
2023-503486-32-00Phase 2Authorised
- Sponsor
- Bioinova
- Start
- Nov 2024
- Modality
- Bone Marrow HSCs → Hematopoietic Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Peripheral Blood HSCs → Hematopoietic Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lenzumestrocel in cartilage defect of knee and knee osteoarthritis (OA) (2 arms), sponsored by Bioinova. Primary endpoints: Lysholm knee function score at 24 months, KOOS score at 24 months and 2 more. Planned start Nov 2024; status: authorised.
02
Drugs
lenzumestrocel
03
Conditions
cartilage defect of kneeknee osteoarthritis (OA)
Beyond the preview
Go deeper on 2023-503486-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503486-32-00.